Keratoconus stabilized by CXL, ribolflavin and UV irradiation

Article

Corneal cross-linking combined with UV-riboflavin is safe and effective in treating keratoconus, reveals the results of a two-year study in Cornea.

Corneal cross-linking combined with UV-riboflavin is safe and effective in treating keratoconus, reveals the results of a two-year study in Cornea.

Dr Yakov Goldich et al., Department of Ophthalmology, Assaf Harofeh Medical Centre, Zerifin, Israel, included 14 eyes of 14 patients in the prospective, clinical-controlled study, with progressive keratoconus. Each patient was treated with CXL after corneal de-epithelization. Uncorrected visual acuity (UCVA) and best spectacle-corrected visual acuity (BSCVA), refraction, biomicroscopy and fundus examination, intraocular pressure, axial length, endothelial cell density, corneal topography, minimal corneal thickness, macular optical coherence tomography and corneal biomechanics were all recorded. Patients were assessed 1 week preoperatively and 1, 3, 6, 9, 12, and 24 postoperatively.

A significant improvement in BCVA was observed when the preoperative results were compared with the two-year postoperative results. UCVA was found to be stable and there was a strong reduction in steepest-meridian keratometry and mean cylinder.

There were no significant changes in mean simulated keratometry, minimal corneal thickness, endothelial cell density, corneal hysteresis and corneal resistance factor or foveal thickness. This suggests that the procedure is safe to conduct in the long term in treating progressive keratoconus.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.